BACKGROUND	Within the prospectively randomized EORTC 62961 phase-III trial , RHT and systemic chemotherapy significantly improved local progression-free survival ( LPFS ) and disease-free survival ( DFS ) in patients with abdominal and extremity sarcomas .\